BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

Rade Drmanac, PhD, Chief Scientific Officer, announced "free three-month trial" program and "reagent rental leasing" program, giving customers the opportun...

January 11, 2023 | News

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is Investigating Other Products Addre...

January 10, 2023 | News

ProPharma Group launches revolutionary new operating model to deliver life-saving drugs, medical devices and diagnostics to market faster

ProPharma Group – the end-to-end, global provider of regulatory, clinical and compliance services for the pharmaceutical, biotechnology and medical d...

January 10, 2023 | News

Cartherics granted first patent in China for multiple development candidates

The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chi...

January 09, 2023 | News

Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering

Under the terms of the Rights Offering, Parnell is extending the expiration date to Wednesday, January 11, 2023 at 5:00 PM (Eastern Time)&nb...

January 09, 2023 | News

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with ...

December 23, 2022 | News

STADA partners with BIAL to bring Ongentys to Parkinson’s patients in Australia

STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...

December 19, 2022 | News

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression ...

December 15, 2022 | News

Data Shows 50% of New Trials Have Sites in Asia Pacific

According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong...

December 15, 2022 | News

Griffith joins $280 million partnership to deliver mRNA vaccine outcomes

The $280 million Translational Science Hub will be established under an agreement between Sanofi, Griffith University, the University of Queensland and the...

December 05, 2022 | News

Inventia enters into a distribution agreement for RASTRUM™ with SCRUM Inc in Japan

RASTRUM™, is a game-changing 3D cell culture platform that’s accelerating the quest to cure cancer and debilitating diseases. With applications...

December 05, 2022 | News

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer tre...

December 02, 2022 | News

Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

Polytaxel, a novel pain-free anticancer drug, may not require break periods A new standard of care, more convenient than docetaxel, is suggest...

November 28, 2022 | News

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) of Australia for the indication of gl...

November 25, 2022 | News

Stay Connected